Skip to main content

The use of F-arginine and phosphodiesterase inhibitor (dipyridamole) to wean from inhaled nitric oxide

Abstract

A full-term, female neonate developed acute hypoxemic respiratory failure complicated by persistent pulmonary hypertension of the newborn (PPHN), and responded to high-frequency oscillatory ventilation (HFOV) and inhaled nitric oxide (iNO). Discontinuation of iNO was attempted three times and was followed by severe desaturation due to right-to-left shunt through the patent ductus arteriosus and patent foramen ovale. As a result of iNO dependency state and rebound pulmonary hypertension, the neonate was maintained on iNO therapy for dipyridamole alone was unsuccessful. However, successful discontinuation of iNO therapy was achieved by combination of L-Arginine and dipyridamole. Exogeous NO may lead to down regulation of endogenous NO production, and further lead to rapid hydrolization of cyclic guanosine 3′, 5′ monophosphate (cGMP), the smooth muscle relaxant, by the enzyme phosphodiesterase. Moreover L-Arginine, the precursor for the formation of endogenous NO, has been found to be deficient in neonates with PPHN,1,2 so we speculated that by inhibiting phosphodiesterase and administrating L-Arginine smooth muscle relaxation occurred, and consequent weaning from iNO was achieved.

References

  1. Vosatka RJ, Kashyap S, Trifiletti R. Arginine deficiency accompanies persistent pulmonay hypertension of the newborn.Biol Neonate 1994; 66 (2–3): 65–70.

    PubMed  CAS  Google Scholar 

  2. Castillo L, De Rojas-Walker T, Yu YMet al. Whole body arginine metabolism and nitric oxide synthesis in newborns with persistent pulmonary hypertension.Pediatric Research 1995; 38 (1): 17–24.

    PubMed  Article  CAS  Google Scholar 

  3. Kinsella JP, Neish SR, Dunbar I, Shaffer E, Abman SH. Cinical responses to prolonged treatment of persistent plumonary hypertension of the newborn with low dose of inhaled nitric oxide.J Pediatr 1993; 123: 103–108.

    PubMed  Article  CAS  Google Scholar 

  4. Roberts JD, Polaner DM, Lang P, Zapol WM. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn.Lancet 1992; 340: 818–819.

    PubMed  Article  CAS  Google Scholar 

  5. Kinsella JP, Neish SR, Shaffer E, Abman SH. Low-dose of inhalational nitric oxide in persistent pulmonary hypertension of the newborn.Lancet 1992; 340: 819–820.

    PubMed  Article  CAS  Google Scholar 

  6. Griffith TM, Edwards DH, Lewis MJ. Evidence that cyclic guanosine monophosphate (cGMP) mediates endothelium-dependent relaxation.Eur J Pharmacol 1985; 112: 195–202.

    PubMed  Article  CAS  Google Scholar 

  7. Al-Alaiyan S, Al-Omran A, Dyer D. The use of phosphodiesterase inhibitor (dipyridamole) to wean from inhaled nitric oxide.Intensive Care Med 1996; 22: 1093–1095

    PubMed  CAS  Google Scholar 

  8. Bult H, De Meyer GRY, Jordaens FH, Herman AG. Chronic exposure to exogenous nitric oxide may suppress its endogenous release and efficacy.J Cardiovasc Pharmacol 1991; 17 (suppl 3): S79–82.

    CAS  Article  Google Scholar 

  9. McCaffrey MJ, Bose CI, Reiter PD, Stiles AD. Effect of L-Arginine infusion on infants with persistent pulmonary hypertension of the newborn.Biol Neonate 1995; 67 (4): 240–243.

    PubMed  CAS  Article  Google Scholar 

  10. Alfonson S, O’ Brien GS. Mechanism of enhancement of adenosine action by dipyridamole and lidoflazine in dogs.Arch Int Pharmacodyn Ther 1971; 194:181–196.

    Google Scholar 

  11. Klabunder RE. Effects of dipyridamole on postischemic vasodilatation extracellular adenosine.Am J Physiol 1983; 224: H273–280.

    Google Scholar 

  12. Scharder JR, Bernc M, Rubio R. Uptake and metabolism of adenosine by human erythrocyte ghosts.Am J Physiol 1973; 223: 159–166.

    Google Scholar 

  13. Beavo JA, Reifsynder. Primary sequences of cyclic nucleotide phosphodiesterase isoenzymes and the design of selective inhibitors.Trends Pharmacol Sci 1990; 11:150–155.

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Khalid Saidy.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Saidy, K., Al-Alaiyan, S. The use of F-arginine and phosphodiesterase inhibitor (dipyridamole) to wean from inhaled nitric oxide. Indian J Pediatr 68, 175–177 (2001). https://doi.org/10.1007/BF02722041

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02722041

Key words

  • Neonate
  • Pulmonary hypertension
  • Nitric oxide
  • L-Arginine
  • Dipyridamole